RxDoctor Payments DataLook up a doctor →

Jack Whitaker, MD

Cardiovascular Disease · Greeneville, TNNPI 1922064047

Payments from drug & device makers

$403,989in general payments, 2019–2025

Across 840 payments — averaging $480.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$207K
  • Esperion Therapeutics, Inc.$64K
  • Janssen Research & Development, LLC$34K
  • AstraZeneca$24K
  • Boehringer Ingelheim$19K
  • Lilly USA, LLC$18K
  • plus $38K from 34 others
$2,059in research payments, 2019–2025

Across 6 payments — averaging $343.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$2K

What the payments were for

  • Consulting fees$5,3807%
  • Speaking & faculty fees$53,85072%
  • Travel & lodging$4,2126%
  • Food & beverage$11,36515%
  • Education$1160%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$403,989 in reported general payments places this provider in the 90th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$112,988
Medicare patients
855
Services billed
1,765

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban196$201,460
XareltoRivaroxaban64$43,663
EntrestoSacubitril/Valsartan42$42,198
BrilintaTicagrelor36$23,988
OzempicSemaglutide13$16,894
JardianceEmpagliflozin16$16,625
FarxigaDapagliflozin Propanediol12$10,073
Repatha SureclickEvolocumab12$6,489
NexlizetBempedoic Acid/Ezetimibe11$6,066
Famotidine201$2,628
Rosuvastatin Calcium183$2,349
Atorvastatin Calcium196$1,881
Diltiazem 24hr Er (Cd)Diltiazem Hcl58$1,396
Metoprolol Succinate127$1,259
ClopidogrelClopidogrel Bisulfate119$1,254

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$186$201,460196 claims
Johnson & JohnsonXarelto$654$43,66364 claims
NovartisEntresto$206,564$42,19842 claims
AstraZenecaBrilinta, Farxiga$24,325$34,06148 claims
Novo NordiskOzempic$242$16,89413 claims
Boehringer IngelheimJardiance$19,032$16,62516 claims
Esperion Therapeutics, Inc.Nexlizet$63,639$6,06611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Greeneville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →